QuidelOrtho

its InflammaDry test detects elevated MMP-9, an inflammatory marker associated with dry eye disease, though a 2026 industry report flagged a supply disruption affecting at least one distribution channel for the product.

Country: United States
Ticker: QDEL

Commercial InflammaDry MMP-9 test

Coverage

	CN	EU	US
diagnostics-medtech	✓	✓	✓

Regulatorsfdaemanmpa

Verifiable facts

Fact	Value	Source
Revenue	$2.73 billion in annual revenue for 2025	sec.gov
Headcount	approximately 1,200 service employees globally as of December 28, 2025	sec.gov
Production site	Manufacturing facilities in the U.S. (Carlsbad, CA; San Diego, CA; Athens, OH; Raritan, NJ; Rochester, NY; Pompano Beach, FL), U.K. (Pencoed, Wales), and China (Changsha)	sec.gov
Certification	Many manufacturing facilities are certified to ISO 13485:2016 and MDSAP medical device standards	sec.gov
Regulatory approval	Facilities are registered with various regulatory bodies, including the FDA and other international and local public health and regulatory agencies	sec.gov
Capacity	The company believes its plant capacity and available space are sufficient to accommodate current growth, maintain quality and support continuity	sec.gov
Funding	The company acquired InflammaDry for approximately $14 million in cash in 2017	ir.quidelortho.com

Independent sources: sec.gov

Technologies

Name	Cluster	Risk
Tear-fluid biopsy	diagnostics-medtech	Medium	→

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.